In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
In vitro activity of cefiderocol against ceftazidime-avibactam susceptible and resistant KPC-producing Enterobacterales: cross-resistance and synergistic effects
Authors
Keywords
-
Journal
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2021-08-31
DOI
10.1007/s10096-021-04341-z
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- The Burden of the Serious and Difficult-to-Treat Infections and a New Antibiotic Available: Cefiderocol
- (2021) Yasaman Taheri et al. Frontiers in Pharmacology
- Epidemiology and Mechanisms of Ceftazidime–Avibactam Resistance in Gram-Negative Bacteria
- (2021) Tingting Xu et al. Engineering
- Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant Gram-negative bacterial infections
- (2021) Katie A Parsels et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Ceftazidime-avibactam resistance and restoration of carbapenem susceptibility in KPC-producing Klebsiella pneumoniae infections: A case series
- (2021) S.A.V. van Asten et al. JOURNAL OF INFECTION AND CHEMOTHERAPY
- Carbapenemase detection testing in the era of ceftazidime/avibactam-resistant KPC-producing Enterobacterales: A 2-year experience
- (2021) Gabriele Bianco et al. Journal of Global Antimicrobial Resistance
- Cross-resistance to cefiderocol and ceftazidime–avibactam in KPC β-lactamase mutants and the inoculum effect
- (2021) Claire Amaris Hobson et al. CLINICAL MICROBIOLOGY AND INFECTION
- Meropenem-vaborbactam as salvage therapy for ceftazidime-avibactam-, cefiderocol-resistant ST-512 Klebsiella pneumoniae producing KPC-31, a D179Y variant of KPC-3
- (2021) Giusy Tiseo et al. Open Forum Infectious Diseases
- KPC-50 confers resistance to ceftazidime-avibactam associated with reduced carbapenemase activity
- (2020) Laurent Poirel et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Clinical evolution of AmpC-mediated ceftazidime-avibactam and cefiderocol resistance in Enterobacter cloacae complex following exposure to cefepime
- (2020) Ryan K Shields et al. CLINICAL INFECTIOUS DISEASES
- Emergence of ceftazidime/avibactam resistance in KPC-8–producing Klebsiella pneumoniae in South America
- (2020) J. García et al. CLINICAL MICROBIOLOGY AND INFECTION
- Activity of cefiderocol against high-risk clones of multidrug-resistant Enterobacterales, Acinetobacter baumannii, Pseudomonas aeruginosa and Stenotrophomonas maltophilia
- (2020) Mercedes Delgado-Valverde et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Bloodstream infection by two subpopulations of Klebsiella pneumoniae ST1685 carrying KPC-33 or KPC-14 following ceftazidime/avibactam treatment: considerations regarding acquired heteroresistance and choice of carbapenemase detection assay
- (2020) Gabriele Bianco et al. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY
- Cefiderocol Antimicrobial Susceptibility Testing against Multidrug-Resistant Gram-negative Bacilli: A Comparison of Disk Diffusion to Broth Microdilution
- (2020) C. Paul Morris et al. JOURNAL OF CLINICAL MICROBIOLOGY
- Genomic characterization of a KPC-23-producing Klebsiella pneumoniae ST258 clinical isolate resistant to ceftazidime-avibactam
- (2019) Galani Irene et al. CLINICAL MICROBIOLOGY AND INFECTION
- Cefiderocol: Discovery, Chemistry, and In Vivo Profiles of a Novel Siderophore Cephalosporin
- (2019) Takafumi Sato et al. CLINICAL INFECTIOUS DISEASES
- Resistance to Ceftazidime-Avibactam and Underlying Mechanisms
- (2019) Yuhang Wang et al. Journal of Global Antimicrobial Resistance
- Treatment of Infections Caused by Extended-Spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-Producing Enterobacteriaceae
- (2018) Jesús Rodríguez-Baño et al. CLINICAL MICROBIOLOGY REVIEWS
- ARGONAUT-I: Activity of Cefiderocol (S-649266), a Siderophore Cephalosporin, against Gram-Negative Bacteria, Including Carbapenem-Resistant Nonfermenters and Enterobacteriaceae with Defined Extended-Spectrum β-Lactamases and Carbapenemases
- (2018) Michael R. Jacobs et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study)
- (2018) Krystyna M. Kazmierczak et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Activity of the novel siderophore cephalosporin cefiderocol against multidrug-resistant Gram-negative pathogens
- (2017) J. Dobias et al. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
- The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace
- (2017) Latania K. Logan et al. JOURNAL OF INFECTIOUS DISEASES
- When Does 2 Plus 2 Equal 5? A Review of Antimicrobial Synergy Testing
- (2014) C. D. Doern JOURNAL OF CLINICAL MICROBIOLOGY
- Carbapenem resistance in Enterobacteriaceae: here is the storm!
- (2012) Patrice Nordmann et al. TRENDS IN MOLECULAR MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More